PL392882A1 - Nowa krystaliczna i amorficzna postać związku triazolo(4,5-D) pirymidyny - Google Patents

Nowa krystaliczna i amorficzna postać związku triazolo(4,5-D) pirymidyny

Info

Publication number
PL392882A1
PL392882A1 PL392882A PL39288201A PL392882A1 PL 392882 A1 PL392882 A1 PL 392882A1 PL 392882 A PL392882 A PL 392882A PL 39288201 A PL39288201 A PL 39288201A PL 392882 A1 PL392882 A1 PL 392882A1
Authority
PL
Poland
Prior art keywords
triazole
amorphous form
pyrimidine compound
new crystalline
crystalline
Prior art date
Application number
PL392882A
Other languages
English (en)
Inventor
Martin Bohlin
Steve Cosgrove
Bo Lassen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL392882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL392882A1 publication Critical patent/PL392882A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
PL392882A 2000-06-02 2001-05-31 Nowa krystaliczna i amorficzna postać związku triazolo(4,5-D) pirymidyny PL392882A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound

Publications (1)

Publication Number Publication Date
PL392882A1 true PL392882A1 (pl) 2011-03-14

Family

ID=9892841

Family Applications (2)

Application Number Title Priority Date Filing Date
PL392882A PL392882A1 (pl) 2000-06-02 2001-05-31 Nowa krystaliczna i amorficzna postać związku triazolo(4,5-D) pirymidyny
PL01359172A PL359172A1 (pl) 2000-06-02 2001-05-31 Nowa krystaliczna i amorficzna postać związku triazolo (4,5-D) pirymidyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL01359172A PL359172A1 (pl) 2000-06-02 2001-05-31 Nowa krystaliczna i amorficzna postać związku triazolo (4,5-D) pirymidyny

Country Status (36)

Country Link
US (3) US20030181469A1 (pl)
EP (3) EP2292622A1 (pl)
JP (3) JP5036947B2 (pl)
KR (1) KR100781864B1 (pl)
CN (2) CN1817883B (pl)
AR (2) AR032335A1 (pl)
AT (2) ATE555115T1 (pl)
AU (4) AU2001262874B2 (pl)
BG (3) BG65837B1 (pl)
BR (1) BR0111328A (pl)
CA (1) CA2408596C (pl)
CY (1) CY1113047T1 (pl)
CZ (2) CZ307468B6 (pl)
DE (1) DE60117972T2 (pl)
DK (2) DK1289992T3 (pl)
EE (1) EE05222B1 (pl)
ES (2) ES2259031T3 (pl)
GB (1) GB0013407D0 (pl)
HK (2) HK1052347B (pl)
HU (2) HU229374B1 (pl)
IL (4) IL152777A0 (pl)
IS (2) IS2609B (pl)
MX (1) MXPA02011795A (pl)
MY (2) MY140674A (pl)
NO (3) NO323780B1 (pl)
NZ (1) NZ522638A (pl)
PH (1) PH12011000127A1 (pl)
PL (2) PL392882A1 (pl)
PT (2) PT1289992E (pl)
RU (3) RU2325391C2 (pl)
SG (1) SG135965A1 (pl)
SI (2) SI1289992T1 (pl)
SK (1) SK287817B6 (pl)
UA (1) UA73181C2 (pl)
WO (1) WO2001092262A1 (pl)
ZA (1) ZA200209324B (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含***并[4,5-d]嘧啶衍生物之組合物
CA2668180A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
CA2734454C (en) 2008-09-09 2016-09-13 Astrazeneca Ab A process for preparing [1s-[1-alpha,2-alpha,3-beta(1s*,2r*)5-beta]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and to its intermediates
CA2768043A1 (en) 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
MX2012006375A (es) * 2009-12-03 2013-03-21 Astrazeneca Ab Co-cristales de un inhibidor de agregacion de plaquetas de triazolo [4, 5-d] pirimidina.
EP2515871B1 (en) 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
CZ303364B6 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
CN103764149A (zh) 2011-06-01 2014-04-30 阿斯利康(瑞典)有限公司 新型替卡格雷共晶
AU2012343928A1 (en) * 2011-11-30 2014-05-29 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
WO2013150495A2 (en) 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014000719A1 (en) 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
WO2014006091A1 (en) 2012-07-04 2014-01-09 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
WO2014155389A2 (en) * 2013-03-25 2014-10-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN107573333B (zh) * 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
EP3003276A1 (en) 2013-05-29 2016-04-13 ratiopharm GmbH Solid pharmaceutical dosage form
CN106496235A (zh) * 2013-06-03 2017-03-15 杭州领业医药科技有限公司 结晶形态的***[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (en) * 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Preparation of ticagrelor
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
IN2013CH04023A (pl) * 2013-09-10 2015-08-07 Laurus Labs Pvt Ltd
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
US10017515B2 (en) 2014-08-11 2018-07-10 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种***并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
US20190002471A1 (en) * 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
AU2017253367B2 (en) 2016-04-21 2020-04-16 Astrazeneca Ab Orally disintegrating tablets
DK3292867T3 (da) * 2016-09-09 2019-07-22 Univ Liege Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP0840740B1 (en) * 1995-07-11 2002-05-02 AstraZeneca AB New inhibitors of platelet aggregation
JP4125790B2 (ja) * 1996-12-20 2008-07-30 アストラゼネカ・アクチエボラーグ トリアゾロ［４，５−ｄ］ピリミジニル誘導体および医薬としてのその使用
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
DE69809750T2 (de) * 1997-07-25 2003-08-21 Gilead Sciences Inc Nukleotid-analog zusammensetzung und synthese verfahren
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound

Also Published As

Publication number Publication date
AU2007200958B2 (en) 2010-10-07
IS2609B (is) 2010-04-15
RU2325391C2 (ru) 2008-05-27
CZ307468B6 (cs) 2018-09-26
BG111017A (bg) 2011-12-30
CN1432018A (zh) 2003-07-23
IL152777A (en) 2008-11-26
NO323780B1 (no) 2007-07-02
NO20025756L (no) 2003-01-24
MXPA02011795A (es) 2003-04-10
CN1817883B (zh) 2011-10-05
EP2292622A1 (en) 2011-03-09
AU2010257449A1 (en) 2011-01-20
ATE555115T1 (de) 2012-05-15
ATE320430T1 (de) 2006-04-15
RU2418802C2 (ru) 2011-05-20
BR0111328A (pt) 2003-06-10
EP1493745B2 (en) 2021-05-19
BG110440A (bg) 2010-03-31
DE60117972T2 (de) 2006-11-23
HU229374B1 (en) 2013-11-28
HUP0302284A3 (en) 2007-05-29
AR032335A1 (es) 2003-11-05
NZ522638A (en) 2004-06-25
HU230471B1 (hu) 2016-07-28
AR068086A2 (es) 2009-11-04
ES2259031T3 (es) 2006-09-16
SK16852002A3 (sk) 2003-08-05
KR20030007829A (ko) 2003-01-23
JP2014129423A (ja) 2014-07-10
MY148652A (en) 2013-05-15
KR100781864B1 (ko) 2007-12-05
ZA200209324B (en) 2004-02-16
DK1493745T3 (da) 2012-07-16
NO20025756D0 (no) 2002-11-29
ES2384708T3 (es) 2012-07-11
MY140674A (en) 2010-01-15
NO333289B1 (no) 2013-04-29
CN1817883A (zh) 2006-08-16
DK1289992T3 (da) 2006-07-03
EP1289992B1 (en) 2006-03-15
HK1073101A1 (en) 2005-09-23
HUP0302284A2 (hu) 2003-10-28
IS6623A (is) 2002-11-15
NO20120595L (no) 2003-01-24
NO20071547L (no) 2003-01-24
JP5684192B2 (ja) 2015-03-11
SG135965A1 (en) 2007-10-29
CZ304347B6 (cs) 2014-03-19
US20030181469A1 (en) 2003-09-25
IL152777A0 (en) 2003-06-24
AU2001262874B2 (en) 2007-03-22
SI1289992T1 (sl) 2006-08-31
JP2003535092A (ja) 2003-11-25
EE200200665A (et) 2004-06-15
BG107331A (bg) 2003-07-31
AU6287401A (en) 2001-12-11
PT1289992E (pt) 2006-07-31
BG65837B1 (bg) 2010-02-26
UA73181C2 (en) 2005-06-15
CA2408596C (en) 2010-12-21
EE05222B1 (et) 2009-10-15
CN1247583C (zh) 2006-03-29
CA2408596A1 (en) 2001-12-06
EP1493745A1 (en) 2005-01-05
EP1289992A1 (en) 2003-03-12
PH12011000127A1 (en) 2016-08-31
RU2005127356A (ru) 2007-03-10
PL359172A1 (pl) 2004-08-23
JP5036947B2 (ja) 2012-09-26
CZ20120293A3 (pl) 2003-07-16
IL202582A (en) 2012-12-31
AU2010257449B2 (en) 2012-03-22
SI1493745T1 (sl) 2012-08-31
IL187482A (en) 2010-06-16
NO332306B1 (no) 2012-08-20
BG66332B1 (bg) 2013-06-28
IS3019B (is) 2020-02-15
DE60117972D1 (de) 2006-05-11
HK1052347A1 (en) 2003-09-11
CY1113047T1 (el) 2016-04-13
HK1052347B (zh) 2006-09-08
EP1493745B1 (en) 2012-04-25
US7265124B2 (en) 2007-09-04
RU2010150799A (ru) 2012-06-20
IL202582A0 (en) 2010-06-30
SK287817B6 (sk) 2011-11-04
PT1493745E (pt) 2012-06-28
US20070173518A1 (en) 2007-07-26
IS8825A (is) 2009-06-02
WO2001092262A1 (en) 2001-12-06
AU2007200958A1 (en) 2007-03-29
HUP1300386A2 (en) 2003-10-28
JP2012149093A (ja) 2012-08-09
GB0013407D0 (en) 2000-07-26
US20070293513A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
PL392882A1 (pl) Nowa krystaliczna i amorficzna postać związku triazolo(4,5-D) pirymidyny
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
MY121867A (en) Novel triazolo(4,5-d)pyrimidine compounds.
WO2002048147A3 (en) Pyrazolopyridines
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MY137774A (en) Acetylene derivatives having mglur5 antagonistic activity
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2002085843A3 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
HUP0100328A3 (en) Novel triazolo(4,5-d)pyrimidine compounds, and pharmaceutical compositions containing the compounds
HUP0303487A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anthiarhythmic agents and process for preparation of the compounds
AU5539899A (en) Novel triazolo(4,5-(d))pyrimidine compounds
CA2452036A1 (en) 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
HUP0303486A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anti-arrythmic compounds agents
DE69900297T2 (de) Akarizid und insektizid wirksame, substituierte Pyrimidine und Verfahren zu ihrer Herstellung
AU2002214467A1 (en) Novel compounds
EP1466914A4 (en) AMORPHIC SUBSTANCE OF A TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVE
WO2002051845A3 (en) Triazolopyrimidines
IL157843A0 (en) Pesticidal compositions containing silicon compounds
AU2002212941A1 (en) Novel compounds
HUP0400443A3 (en) Pyrazolo[1,2-a][1,2,4]triazole compounds useful as anti-inflammatory agents and pharmaceutical compositions containing them
HUP0402418A3 (en) Substituted 1,5-diaminopentan-3-ol compounds, process for producing them, pharmaceutical compositions containing them and use thereof
AU2002257753A1 (en) Use of substituted imidazo(1,2-A)-pyridine compounds as medicaments
GB0115897D0 (en) Process for the preparation of chemical compounds

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)